|
G |
Cda |
cytidine deaminase |
increases metabolic processing |
ISO |
CDA protein results in increased metabolism of 5-fluorocytidine |
CTD |
PMID:21804305 |
|
NCBI chr 5:156,703,579...156,734,541
Ensembl chr 5:156,703,579...156,734,541 Ensembl chr 5:156,703,579...156,734,541
|
|
|
G |
Abcc5 |
ATP binding cassette subfamily C member 5 |
increases export |
ISO |
ABCC5 protein results in increased export of 5-fluorouridine |
CTD |
PMID:15897250 |
|
NCBI chr11:84,395,982...84,490,215
Ensembl chr11:84,396,033...84,490,211
|
|
G |
Sod1 |
superoxide dismutase 1 |
affects binding |
ISO |
5-fluorouridine binds to SOD1 protein; 5-fluorouridine binds to SOD1 protein mutant form |
CTD |
PMID:23612299 |
|
NCBI chr11:30,363,282...30,368,858
Ensembl chr11:30,363,280...30,368,862
|
|
|
G |
Abcb7 |
ATP binding cassette subfamily B member 7 |
decreases response to substance |
ISO |
ABCB7 protein results in decreased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr X:75,150,511...75,291,950
Ensembl chr X:75,150,608...75,291,938
|
|
G |
Acaa1a |
acetyl-CoA acyltransferase 1A |
increases response to substance |
ISO |
ACAA1 protein results in increased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr 8:128,027,880...128,036,471
Ensembl chr 8:128,027,958...128,036,236
|
|
G |
Agpat2 |
1-acylglycerol-3-phosphate O-acyltransferase 2 |
increases response to substance |
ISO |
AGPAT2 protein results in increased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr 3:4,044,741...4,055,384
Ensembl chr 3:4,044,542...4,055,806
|
|
G |
Agr2 |
anterior gradient 2, protein disulphide isomerase family member |
increases response to substance |
ISO |
AGR2 protein results in increased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr 6:55,465,782...55,487,087
Ensembl chr 6:55,465,782...55,487,714
|
|
G |
Akr1b1 |
aldo-keto reductase family 1 member B |
decreases response to substance |
ISO |
AKR1B1 protein results in decreased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr 4:61,706,866...61,720,959
Ensembl chr 4:61,706,864...61,720,956
|
|
G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
increases response to substance |
ISO |
AKR1C3 protein results in increased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr17:69,761,126...69,778,021
Ensembl chr17:69,761,118...69,778,021
|
|
G |
Arl4d |
ADP-ribosylation factor like GTPase 4D |
decreases response to substance |
ISO |
ARL4D protein results in decreased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr10:89,577,556...89,580,368
Ensembl chr10:89,578,212...89,580,368
|
|
G |
Axl |
Axl receptor tyrosine kinase |
decreases response to substance |
ISO |
AXL protein results in decreased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr 1:82,550,892...82,580,761
Ensembl chr 1:82,549,420...82,580,761
|
|
G |
Canx |
calnexin |
multiple interactions |
ISO |
CANX results in decreased susceptibility to [Fluorouracil co-treated with Capecitabine] |
CTD |
PMID:18678097 |
|
NCBI chr10:35,800,942...35,833,939
Ensembl chr10:35,800,942...35,833,861
|
|
G |
Ccn1 |
cellular communication network factor 1 |
decreases response to substance |
ISO |
CCN1 protein results in decreased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr 2:251,529,354...251,532,312
Ensembl chr 2:251,529,354...251,532,312
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
decreases expression |
ISO |
Capecitabine results in decreased expression of CDKN2A protein |
CTD |
PMID:17904787 |
|
NCBI chr 5:107,823,323...107,832,405
Ensembl chr 5:107,823,330...107,841,175
|
|
G |
Ces1d |
carboxylesterase 1D |
multiple interactions |
ISO |
CES1 protein results in increased hydrolysis of and results in increased activity of Capecitabine |
CTD |
PMID:15687373 |
|
NCBI chr19:15,195,514...15,239,827
Ensembl chr19:15,033,108...15,239,821
|
|
G |
Ces2h |
carboxylesterase 2H |
multiple interactions increases response to substance |
ISO |
CES2 protein results in increased hydrolysis of and results in increased activity of Capecitabine CES2 gene polymorphism results in increased susceptibility to Capecitabine |
CTD |
PMID:15687373 PMID:18473752 |
|
NCBI chr19:37,052,555...37,067,176
Ensembl chr19:37,052,556...37,067,156
|
|
G |
Cib1 |
calcium and integrin binding 1 |
increases response to substance |
ISO |
CIB1 protein results in increased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr 1:142,014,962...142,020,461
Ensembl chr 1:142,014,958...142,020,525
|
|
G |
Cldn3 |
claudin 3 |
increases response to substance |
ISO |
CLDN3 protein results in increased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr12:21,831,341...21,832,813
Ensembl chr12:21,831,342...21,832,813
|
|
G |
Dpyd |
dihydropyrimidine dehydrogenase |
increases expression decreases response to substance affects response to substance |
ISO |
Capecitabine results in increased expression of DPYD mRNA DPYD protein results in decreased susceptibility to Capecitabine DPYD protein affects the susceptibility to Capecitabine |
CTD |
PMID:16734730 PMID:17611699 PMID:18846242 |
|
NCBI chr 2:221,823,692...222,694,627
Ensembl chr 2:221,823,687...222,694,627
|
|
G |
Dse |
dermatan sulfate epimerase |
decreases response to substance |
ISO |
DSE protein results in decreased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr20:27,703,738...27,784,982
Ensembl chr20:27,703,732...27,782,586
|
|
G |
Eps8 |
epidermal growth factor receptor pathway substrate 8 |
increases response to substance |
ISO |
EPS8 protein results in increased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr 4:171,475,155...171,645,620
Ensembl chr 4:171,475,567...171,591,882
|
|
G |
Erbb3 |
erb-b2 receptor tyrosine kinase 3 |
increases response to substance |
ISO |
ERBB3 protein results in increased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr 7:2,989,202...3,010,610
Ensembl chr 7:2,989,340...3,010,350
|
|
G |
Fhl1 |
four and a half LIM domains 1 |
decreases response to substance |
ISO |
FHL1 protein results in decreased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr X:159,112,516...159,172,528
Ensembl chr X:159,112,880...159,172,524
|
|
G |
Flii |
FLII, actin remodeling protein |
decreases response to substance |
ISO |
FLII protein results in decreased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr10:46,955,460...46,969,468
Ensembl chr10:46,955,487...46,969,406
|
|
G |
Fuca1 |
alpha-L-fucosidase 1 |
increases response to substance |
ISO |
FUCA1 protein results in increased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr 5:154,269,296...154,286,545
Ensembl chr 5:154,269,118...154,286,544
|
|
G |
Hdgfl3 |
HDGF like 3 |
decreases response to substance |
ISO |
HDGFL3 protein results in decreased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr 1:143,702,864...143,752,060
Ensembl chr 1:143,702,853...143,751,789
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
decreases response to substance |
ISO |
HIF1A protein results in decreased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr 6:96,810,868...96,856,303
Ensembl chr 6:96,810,907...96,856,052
|
|
G |
Hras |
HRas proto-oncogene, GTPase |
decreases response to substance |
ISO |
HRAS protein results in decreased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr 1:214,178,404...214,181,841
Ensembl chr 1:214,178,407...214,181,686
|
|
G |
Il17rb |
interleukin 17 receptor B |
increases response to substance |
ISO |
IL17RB protein results in increased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr16:6,064,287...6,077,978
Ensembl chr16:6,064,288...6,077,978
|
|
G |
Il1r2 |
interleukin 1 receptor type 2 |
increases response to substance |
ISO |
IL1R2 protein results in increased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr 9:46,840,646...46,881,241
Ensembl chr 9:46,840,992...46,881,264
|
|
G |
Junb |
JunB proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
JUNB results in decreased susceptibility to [Fluorouracil co-treated with Capecitabine] |
CTD |
PMID:18678097 |
|
NCBI chr19:26,092,972...26,094,756
Ensembl chr19:26,092,974...26,094,756
|
|
G |
Lgals4 |
galectin 4 |
increases response to substance |
ISO |
LGALS4 protein results in increased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr 1:87,019,598...87,027,720
Ensembl chr 1:87,019,975...87,027,691
|
|
G |
Mdm4 |
MDM4 regulator of p53 |
multiple interactions |
ISO |
MDM4 results in decreased susceptibility to [Fluorouracil co-treated with Capecitabine] |
CTD |
PMID:18678097 |
|
NCBI chr13:49,786,776...49,828,780
Ensembl chr13:49,792,794...49,828,720
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
ISO |
MMP2 results in decreased susceptibility to [Fluorouracil co-treated with Capecitabine] |
CTD |
PMID:18678097 |
|
NCBI chr19:15,542,771...15,570,589
Ensembl chr19:15,542,765...15,570,611
|
|
G |
Mre11 |
MRE11 homolog, double strand break repair nuclease |
decreases response to substance |
ISO |
MRE11 protein results in decreased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr 8:13,304,355...13,350,329
Ensembl chr 8:13,305,152...13,352,489
|
|
G |
Myb |
MYB proto-oncogene, transcription factor |
increases response to substance |
ISO |
MYB protein results in increased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr 1:16,658,178...16,690,135
Ensembl chr 1:16,659,442...16,687,817
|
|
G |
Myrf |
myelin regulatory factor |
increases response to substance |
ISO |
MYRF protein results in increased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr 1:226,260,558...226,292,650
Ensembl chr 1:226,260,558...226,292,480
|
|
G |
Pkd2 |
polycystin 2, transient receptor potential cation channel |
decreases response to substance |
ISO |
PKD2 protein results in decreased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr14:6,602,004...6,645,257
Ensembl chr14:6,602,004...6,645,257
|
|
G |
Pkp2 |
plakophilin 2 |
increases response to substance |
ISO |
PKP2 protein results in increased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr11:88,912,163...88,972,213
|
|
G |
Plce1 |
phospholipase C, epsilon 1 |
increases response to substance |
ISO |
PLCE1 protein results in increased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr 1:257,156,023...257,465,440
Ensembl chr 1:257,157,264...257,466,064
|
|
G |
Ppa1 |
inorganic pyrophosphatase 1 |
increases response to substance |
ISO |
PPA1 protein results in increased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr20:31,265,519...31,292,451
Ensembl chr20:31,265,483...31,310,674
|
|
G |
Prkacb |
protein kinase cAMP-activated catalytic subunit beta |
decreases response to substance |
ISO |
PRKACB protein results in decreased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr 2:252,602,197...252,691,886
Ensembl chr 2:252,605,307...252,691,886
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
decreases expression |
ISO |
Capecitabine results in decreased expression of PTGS2 protein |
CTD |
PMID:17904787 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Ptpn13 |
protein tyrosine phosphatase, non-receptor type 13 |
decreases response to substance |
ISO |
PTPN13 protein results in decreased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr14:7,688,551...7,863,664
Ensembl chr14:7,688,551...7,863,664
|
|
G |
Pygb |
glycogen phosphorylase B |
increases response to substance |
ISO |
PYGB protein results in increased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr 3:146,581,063...146,629,504
Ensembl chr 3:146,582,752...146,634,535
|
|
G |
Rab40b |
Rab40b, member RAS oncogene family |
increases response to substance |
ISO |
RAB40B protein results in increased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr10:110,557,798...110,585,424
Ensembl chr10:110,557,729...110,585,376
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
multiple interactions |
ISO |
RB1 results in decreased susceptibility to [Fluorouracil co-treated with Capecitabine] |
CTD |
PMID:18678097 |
|
NCBI chr15:55,081,582...55,209,060
Ensembl chr15:55,083,140...55,209,342
|
|
G |
Rbbp4 |
RB binding protein 4, chromatin remodeling factor |
multiple interactions |
ISO |
RBBP4 results in decreased susceptibility to [Fluorouracil co-treated with Capecitabine] |
CTD |
PMID:18678097 |
|
NCBI chr 5:147,499,880...147,535,240
Ensembl chr 5:147,499,882...147,535,240
|
|
G |
Rpa1 |
replication protein A1 |
decreases response to substance |
ISO |
RPA1 protein results in decreased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr10:62,140,419...62,191,518
Ensembl chr10:62,140,419...62,191,512
|
|
G |
Rras2 |
RAS related 2 |
decreases response to substance |
ISO |
RRAS2 protein results in decreased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr 1:178,940,515...179,010,257
Ensembl chr 1:178,940,516...179,010,257
|
|
G |
Slco2b1 |
solute carrier organic anion transporter family, member 2b1 |
multiple interactions |
ISO |
Capecitabine inhibits the reaction [SLCO2B1 protein results in increased uptake of Cascade Blue] |
CTD |
PMID:30863990 |
|
NCBI chr 1:164,623,313...164,671,612
Ensembl chr 1:164,623,599...164,671,577
|
|
G |
Stip1 |
stress-induced phosphoprotein 1 |
decreases response to substance |
ISO |
STIP1 protein results in decreased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr 1:222,274,133...222,293,139
Ensembl chr 1:222,274,133...222,293,148
|
|
G |
Tcf7l2 |
transcription factor 7 like 2 |
multiple interactions |
ISO |
TCF7L2 results in decreased susceptibility to [Fluorouracil co-treated with Capecitabine] |
CTD |
PMID:18678097 |
|
NCBI chr 1:276,686,911...276,730,517
Ensembl chr 1:276,659,542...276,730,514 Ensembl chr 1:276,659,542...276,730,514
|
|
G |
Tead1 |
TEA domain transcription factor 1 |
decreases response to substance |
ISO |
TEAD1 protein results in decreased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr 1:177,495,500...177,714,795
Ensembl chr 1:177,495,782...177,707,061
|
|
G |
Tff1 |
trefoil factor 1 |
increases response to substance |
ISO |
TFF1 protein results in increased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr20:9,892,124...9,895,984
Ensembl chr20:9,892,124...9,895,984
|
|
G |
Trim15 |
tripartite motif containing 15 |
increases response to substance |
ISO |
TRIM15 protein results in increased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr20:2,194,293...2,203,636
Ensembl chr20:2,194,709...2,201,668
|
|
G |
Tyms |
thymidylate synthetase |
affects expression decreases response to substance multiple interactions |
ISO |
Capecitabine affects the expression of TYMS mRNA TYMS protein results in decreased susceptibility to Capecitabine [TYMS enhancer polymorphism co-treated with VEGFA gene SNP] affects the susceptibility to [Capecitabine co-treated with oxaliplatin] |
CTD |
PMID:16438929 PMID:16734730 PMID:21048041 |
|
NCBI chr 9:121,918,875...121,931,564
Ensembl chr 9:121,918,947...121,931,564
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
[TYMS enhancer polymorphism co-treated with VEGFA gene SNP] affects the susceptibility to [Capecitabine co-treated with oxaliplatin] |
CTD |
PMID:21048041 |
|
NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
|
|
G |
Zfp706 |
zinc finger protein 706 |
increases response to substance |
ISO |
ZNF706 protein results in increased susceptibility to Capecitabine |
CTD |
PMID:16734730 |
|
NCBI chr 7:75,803,310...75,809,853
Ensembl chr 7:75,801,735...75,809,836
|
|
|
G |
Adora1 |
adenosine A1 receptor |
increases activity |
EXP |
Cytidine results in increased activity of ADORA1 protein |
CTD |
PMID:18313046 |
|
NCBI chr13:51,042,111...51,076,913
Ensembl chr13:51,042,248...51,076,852
|
|
G |
Adora2a |
adenosine A2a receptor |
increases activity |
EXP |
Cytidine results in increased activity of ADORA2A protein |
CTD |
PMID:18313046 |
|
NCBI chr20:14,265,251...14,282,873
Ensembl chr20:14,265,252...14,282,873
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions |
ISO |
[Chlorine binds to Cytidine] which results in decreased expression of CCL5 mRNA |
CTD |
PMID:31066272 |
|
NCBI chr10:70,739,764...70,744,303
Ensembl chr10:70,739,800...70,744,315
|
|
G |
Gypa |
glycophorin A |
multiple interactions |
ISO |
Cytidine inhibits the reaction [A 771726 results in increased expression of GYPA protein] |
CTD |
PMID:12181422 |
|
NCBI chr19:31,115,545...31,131,079
|
|
G |
Idh2 |
isocitrate dehydrogenase (NADP(+)) 2 |
increases abundance multiple interactions |
ISO |
IDH2 protein mutant form results in increased abundance of Cytidine Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Cytidine] |
CTD |
PMID:27469509 |
|
NCBI chr 1:141,874,354...141,893,674
Ensembl chr 1:141,866,283...141,893,705
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
[Chlorine binds to Cytidine] which results in increased expression of IL1B mRNA; [Chlorine binds to Cytidine] which results in increased expression of IL1B protein |
CTD |
PMID:31066272 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Slc28a1 |
solute carrier family 28 member 1 |
multiple interactions increases transport |
ISO |
Cytidine inhibits the reaction [SLC28A1 protein results in increased uptake of Uridine] SLC28A1 protein results in increased transport of Cytidine |
CTD |
PMID:9124315 PMID:10772724 |
|
NCBI chr 1:142,948,942...142,992,410
Ensembl chr 1:142,950,540...142,992,615
|
|
G |
Slc29a1 |
solute carrier family 29 member 1 |
multiple interactions |
ISO EXP |
Cytidine inhibits the reaction [SLC29A1 protein results in increased uptake of Uridine] |
CTD |
PMID:9353301 PMID:11085929 |
|
NCBI chr 9:17,784,468...17,799,008
Ensembl chr 9:17,784,468...17,799,005
|
|
G |
Slc29a2 |
solute carrier family 29 member 2 |
multiple interactions |
ISO |
Cytidine inhibits the reaction [SLC29A2 protein results in increased uptake of Uridine] |
CTD |
PMID:11085929 |
|
NCBI chr 1:220,306,622...220,314,631
Ensembl chr 1:220,400,855...220,407,189 Ensembl chr 1:220,400,855...220,407,189
|
|
G |
Upp1 |
uridine phosphorylase 1 |
increases metabolic processing |
ISO |
UPP1 protein results in increased metabolism of Cytidine |
CTD |
PMID:15772079 |
|
NCBI chr14:89,314,234...89,334,060
Ensembl chr14:89,314,176...89,334,276
|
|
|
G |
Klrc1 |
killer cell lectin like receptor C1 |
decreases expression |
ISO |
sofosbuvir co-treated with ledipasvir decreased expression of NCR1 protein in natural killer cells |
RGD |
PMID:31218578 |
RGD:40400920 |
NCBI chr 4:163,453,435...163,463,718
Ensembl chr 4:163,458,528...163,463,718
|
|
G |
Ncr1 |
natural cytotoxicity triggering receptor 1 |
affects expression |
ISO |
sofosbuvir co-treated with ledipasvir affects expression of NCR1 protein in natural killer cells |
RGD |
PMID:31218578 |
RGD:40400920 |
NCBI chr 1:73,178,917...73,226,504
Ensembl chr 1:73,179,013...73,226,777
|
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
multiple interactions |
ISO |
P2RY6 gene affects the reaction [Uridine Diphosphate promotes the reaction [Lipopolysaccharides results in increased secretion of CXCL2 protein]]; Uridine Diphosphate promotes the reaction [Lipopolysaccharides results in increased secretion of CXCL2 protein] |
CTD |
PMID:18523137 |
|
NCBI chr14:18,731,346...18,733,391
Ensembl chr14:18,731,378...18,733,391
|
|
G |
Cysltr1 |
cysteinyl leukotriene receptor 1 |
multiple interactions |
ISO |
[Uridine Diphosphate binds to and results in increased activity of CYSLTR1 protein] which results in increased abundance of Calcium; [Uridine Diphosphate binds to and results in increased activity of CYSLTR1 protein] which results in increased expression of CXCL8 protein; montelukast inhibits the reaction [[Uridine Diphosphate binds to and results in increased activity of CYSLTR1 protein] which results in increased abundance of Calcium]; montelukast inhibits the reaction [[Uridine Diphosphate metabolite results in increased activity of CYSLTR1 protein] which results in increased expression of CXCL8 protein]; Uridine Diphosphate binds to and results in increased activity of CYSLTR1 protein; zafirlukast inhibits the reaction [[Uridine Diphosphate binds to and results in increased activity of CYSLTR1 protein] which results in increased abundance of Calcium]; zafirlukast inhibits the reaction [[Uridine Diphosphate metabolite results in increased activity of CYSLTR1 protein] which results in increased expression of CXCL8 protein] |
CTD |
PMID:20083671 |
|
NCBI chr X:77,671,028...77,700,491
Ensembl chr X:77,674,150...77,700,269
|
|
G |
Gpr17 |
G protein-coupled receptor 17 |
multiple interactions |
ISO |
cangrelor inhibits the reaction [Uridine Diphosphate results in increased activity of GPR17 protein] |
CTD |
PMID:18974869 |
|
NCBI chr18:24,733,306...24,739,194
Ensembl chr18:24,734,330...24,735,349
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions |
ISO |
Uridine Diphosphate inhibits the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form] |
CTD |
PMID:32941855 |
|
NCBI chr 8:48,665,652...48,666,981
Ensembl chr 8:48,665,652...48,666,981
|
|
G |
Idh2 |
isocitrate dehydrogenase (NADP(+)) 2 |
increases abundance multiple interactions |
ISO |
IDH2 protein mutant form results in increased abundance of Uridine Diphosphate Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Uridine Diphosphate] |
CTD |
PMID:27469509 |
|
NCBI chr 1:141,874,354...141,893,674
Ensembl chr 1:141,866,283...141,893,705
|
|
G |
Il6 |
interleukin 6 |
multiple interactions increases expression |
ISO |
MRS 2211 inhibits the reaction [Uridine Diphosphate results in increased expression of IL6 protein]; P2RY6 gene affects the reaction [Uridine Diphosphate promotes the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]]; Uridine Diphosphate promotes the reaction [Lipopolysaccharides results in increased secretion of IL6 protein] |
CTD |
PMID:18523137 PMID:24849676 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation multiple interactions |
ISO |
Uridine Diphosphate results in increased phosphorylation of MAPK1 protein P2RY6 gene mutant form inhibits the reaction [Uridine Diphosphate results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:15034929 PMID:18523137 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation multiple interactions |
ISO |
Uridine Diphosphate results in increased phosphorylation of MAPK3 protein P2RY6 gene mutant form inhibits the reaction [Uridine Diphosphate results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:15034929 PMID:18523137 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
P2ry6 |
pyrimidinergic receptor P2Y6 |
multiple interactions affects response to substance |
ISO |
P2RY6 gene affects the reaction [Uridine Diphosphate promotes the reaction [Lipopolysaccharides results in increased secretion of CXCL2 protein]]; P2RY6 gene affects the reaction [Uridine Diphosphate promotes the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]]; P2RY6 gene mutant form inhibits the reaction [Uridine Diphosphate results in increased phosphorylation of MAPK1 protein]; P2RY6 gene mutant form inhibits the reaction [Uridine Diphosphate results in increased phosphorylation of MAPK3 protein] P2RY6 gene affects the susceptibility to Uridine Diphosphate |
CTD |
PMID:18523137 |
|
NCBI chr 1:165,972,439...166,008,348
Ensembl chr 1:165,972,440...165,997,751
|
|
G |
Tp53bp1 |
tumor protein p53 binding protein 1 |
multiple interactions |
ISO |
Uridine Diphosphate inhibits the reaction [Cesium-137 results in increased expression of and affects the localization of TP53BP1 protein] |
CTD |
PMID:32941855 |
|
NCBI chr 3:113,160,030...113,259,701
Ensembl chr 3:113,160,000...113,231,790
|
|
|
G |
Gale |
UDP-galactose-4-epimerase |
affects binding |
ISO |
Uridine Diphosphate Galactose binds to GALE protein |
CTD |
PMID:25526675 |
|
NCBI chr 5:154,310,453...154,314,959
Ensembl chr 5:154,310,453...154,314,955
|
|
G |
Gpr17 |
G protein-coupled receptor 17 |
increases activity |
ISO |
Uridine Diphosphate Galactose results in increased activity of GPR17 protein |
CTD |
PMID:18974869 |
|
NCBI chr18:24,733,306...24,739,194
Ensembl chr18:24,734,330...24,735,349
|
|
G |
Uxs1 |
UDP-glucuronate decarboxylase 1 |
multiple interactions |
ISO |
[Uridine Diphosphate Galactose co-treated with NAD] binds to UXS1 protein |
CTD |
PMID:25526675 |
|
NCBI chr 9:11,165,006...11,240,329
Ensembl chr 9:11,164,715...11,339,790
|
|
|
G |
Gale |
UDP-galactose-4-epimerase |
affects binding |
ISO |
Uridine Diphosphate Glucose binds to GALE protein |
CTD |
PMID:25526675 |
|
NCBI chr 5:154,310,453...154,314,959
Ensembl chr 5:154,310,453...154,314,955
|
|
G |
Gpr17 |
G protein-coupled receptor 17 |
increases activity |
ISO |
Uridine Diphosphate Glucose results in increased activity of GPR17 protein |
CTD |
PMID:18974869 |
|
NCBI chr18:24,733,306...24,739,194
Ensembl chr18:24,734,330...24,735,349
|
|
G |
Uxs1 |
UDP-glucuronate decarboxylase 1 |
multiple interactions |
ISO |
[Uridine Diphosphate Glucose co-treated with NAD] binds to UXS1 protein |
CTD |
PMID:25526675 |
|
NCBI chr 9:11,165,006...11,240,329
Ensembl chr 9:11,164,715...11,339,790
|
|
|
G |
B3gat3 |
beta-1,3-glucuronyltransferase 3 |
affects binding multiple interactions |
ISO |
B3GAT3 protein binds to Uridine Diphosphate Glucuronic Acid Uridine Diphosphate Glucuronic Acid inhibits the reaction [Diacetyl results in decreased activity of B3GAT3 protein] |
CTD |
PMID:11986319 |
|
NCBI chr 1:225,120,061...225,126,579
Ensembl chr 1:225,120,061...225,126,579
|
|
G |
Gale |
UDP-galactose-4-epimerase |
affects binding |
ISO |
Uridine Diphosphate Glucuronic Acid binds to GALE protein |
CTD |
PMID:25526675 |
|
NCBI chr 5:154,310,453...154,314,959
Ensembl chr 5:154,310,453...154,314,955
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
increases expression |
ISO |
Uridine Diphosphate Glucuronic Acid results in increased expression of PPARGC1A mRNA |
CTD |
PMID:23056435 |
|
NCBI chr14:63,095,291...63,190,688
Ensembl chr14:63,095,720...63,187,009
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
multiple interactions |
ISO |
[Uridine Diphosphate Glucuronic Acid co-treated with UGT1A1 protein] results in increased glucuronidation of Labetalol |
CTD |
PMID:18098064 |
|
NCBI chr 9:95,295,701...95,302,822
Ensembl chr 9:95,161,157...95,302,822
|
|
G |
Ugt2b7 |
UDP glucuronosyltransferase family 2 member B7 |
multiple interactions |
ISO |
[Uridine Diphosphate Glucuronic Acid co-treated with UGT2B7 protein] results in increased glucuronidation of Labetalol; Fluconazole inhibits the reaction [[Uridine Diphosphate Glucuronic Acid co-treated with UGT2B7 protein] results in increased glucuronidation of Labetalol] |
CTD |
PMID:18098064 |
|
NCBI chr14:22,597,103...22,619,968
|
|
G |
Uxs1 |
UDP-glucuronate decarboxylase 1 |
multiple interactions |
ISO |
[Uridine Diphosphate Glucuronic Acid co-treated with NAD] binds to UXS1 protein |
CTD |
PMID:25526675 |
|
NCBI chr 9:11,165,006...11,240,329
Ensembl chr 9:11,164,715...11,339,790
|
|
|
G |
Gale |
UDP-galactose-4-epimerase |
affects binding |
ISO |
Uridine Diphosphate Galactose binds to GALE protein |
CTD |
PMID:25526675 |
|
NCBI chr 5:154,310,453...154,314,959
Ensembl chr 5:154,310,453...154,314,955
|
|
G |
Gpr17 |
G protein-coupled receptor 17 |
increases activity |
ISO |
Uridine Diphosphate Galactose results in increased activity of GPR17 protein |
CTD |
PMID:18974869 |
|
NCBI chr18:24,733,306...24,739,194
Ensembl chr18:24,734,330...24,735,349
|
|
G |
Uxs1 |
UDP-glucuronate decarboxylase 1 |
multiple interactions |
ISO |
[Uridine Diphosphate Galactose co-treated with NAD] binds to UXS1 protein |
CTD |
PMID:25526675 |
|
NCBI chr 9:11,165,006...11,240,329
Ensembl chr 9:11,164,715...11,339,790
|
|
|
G |
Gale |
UDP-galactose-4-epimerase |
affects binding |
ISO |
Uridine Diphosphate Glucose binds to GALE protein |
CTD |
PMID:25526675 |
|
NCBI chr 5:154,310,453...154,314,959
Ensembl chr 5:154,310,453...154,314,955
|
|
G |
Gpr17 |
G protein-coupled receptor 17 |
increases activity |
ISO |
Uridine Diphosphate Glucose results in increased activity of GPR17 protein |
CTD |
PMID:18974869 |
|
NCBI chr18:24,733,306...24,739,194
Ensembl chr18:24,734,330...24,735,349
|
|
G |
Uxs1 |
UDP-glucuronate decarboxylase 1 |
multiple interactions |
ISO |
[Uridine Diphosphate Glucose co-treated with NAD] binds to UXS1 protein |
CTD |
PMID:25526675 |
|
NCBI chr 9:11,165,006...11,240,329
Ensembl chr 9:11,164,715...11,339,790
|
|
|
G |
Gale |
UDP-galactose-4-epimerase |
affects binding |
ISO |
Uridine Diphosphate N-Acetylgalactosamine binds to GALE protein |
CTD |
PMID:25526675 |
|
NCBI chr 5:154,310,453...154,314,959
Ensembl chr 5:154,310,453...154,314,955
|
|
|
G |
Idh2 |
isocitrate dehydrogenase (NADP(+)) 2 |
multiple interactions increases abundance |
ISO |
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Uridine Diphosphate N-Acetylglucosamine] |
CTD |
PMID:27469509 |
|
NCBI chr 1:141,874,354...141,893,674
Ensembl chr 1:141,866,283...141,893,705
|
|
|
G |
Adora1 |
adenosine A1 receptor |
increases activity |
EXP |
Uridine results in increased activity of ADORA1 protein |
CTD |
PMID:18313046 |
|
NCBI chr13:51,042,111...51,076,913
Ensembl chr13:51,042,248...51,076,852
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
Uridine inhibits the reaction [tripterine results in increased expression of BAX protein] |
CTD |
PMID:27374097 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
Uridine inhibits the reaction [tripterine results in increased cleavage of CASP3 protein] |
CTD |
PMID:27374097 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
Uridine inhibits the reaction [tripterine results in increased cleavage of CASP9 protein] |
CTD |
PMID:27374097 |
|
NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
|
|
G |
Col2a1 |
collagen type II alpha 1 chain |
multiple interactions |
EXP |
[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Uridine; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Uridine]; Dexamethasone inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Uridine]; huang-lien-chieh-tu-tang inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Uridine] |
CTD |
PMID:24709313 |
|
NCBI chr 7:139,454,945...139,484,403
Ensembl chr 7:139,455,242...139,483,997
|
|
G |
Faslg |
Fas ligand |
increases expression |
ISO |
Uridine results in increased expression of FASLG protein |
CTD |
PMID:16419169 |
|
NCBI chr13:79,696,811...79,717,581
Ensembl chr13:79,698,445...79,705,705
|
|
G |
Gypa |
glycophorin A |
multiple interactions |
ISO |
Uridine inhibits the reaction [A 771726 results in increased expression of GYPA protein] |
CTD |
PMID:12181422 |
|
NCBI chr19:31,115,545...31,131,079
|
|
G |
Idh2 |
isocitrate dehydrogenase (NADP(+)) 2 |
multiple interactions increases abundance |
ISO |
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Uridine] |
CTD |
PMID:27469509 |
|
NCBI chr 1:141,874,354...141,893,674
Ensembl chr 1:141,866,283...141,893,705
|
|
G |
Mt-co1 |
mitochondrially encoded cytochrome c oxidase I |
multiple interactions |
ISO |
Uridine inhibits the reaction [Zalcitabine results in decreased expression of COX1 protein]; Uridine inhibits the reaction [Zidovudine results in decreased expression of COX1 protein] |
CTD |
PMID:17187420 PMID:18163507 PMID:20032772 |
|
NCBI chr MT:5,323...6,867
Ensembl chr MT:5,323...6,867
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions |
ISO |
Uridine inhibits the reaction [Adenosine results in decreased expression of MYC protein] |
CTD |
PMID:9808420 |
|
NCBI chr 7:102,586,313...102,591,240
Ensembl chr 7:102,586,313...102,591,240
|
|
G |
Slc28a1 |
solute carrier family 28 member 1 |
multiple interactions increases uptake increases export increases transport |
ISO EXP |
Adenosine inhibits the reaction [SLC28A1 protein results in increased uptake of Uridine]; Cytarabine inhibits the reaction [SLC28A1 protein results in increased transport of Uridine]; Cytidine inhibits the reaction [SLC28A1 protein results in increased uptake of Uridine]; gemcitabine inhibits the reaction [SLC28A1 protein results in increased transport of Uridine]; Lamivudine inhibits the reaction [SLC28A1 protein results in increased transport of Uridine]; Sodium affects the reaction [SLC28A1 protein results in increased uptake of Uridine]; Thymidine inhibits the reaction [SLC28A1 protein results in increased uptake of Uridine]; Zidovudine inhibits the reaction [SLC28A1 protein results in increased uptake of Uridine] SLC28A1 protein results in increased export of Uridine Cytarabine inhibits the reaction [SLC28A1 protein results in increased uptake of Uridine]; gemcitabine inhibits the reaction [SLC28A1 protein results in increased uptake of Uridine]; Idoxuridine inhibits the reaction [SLC28A1 protein results in increased uptake of Uridine]; Zalcitabine inhibits the reaction [SLC28A1 protein results in increased uptake of Uridine]; Zalcitabine promotes the reaction [SLC28A1 protein results in increased export of Uridine]; Zidovudine inhibits the reaction [SLC28A1 protein results in increased uptake of Uridine]; Zidovudine promotes the reaction [SLC28A1 protein results in increased export of Uridine] |
CTD |
PMID:8700147 PMID:8713072 PMID:9124315 PMID:10772724 |
|
NCBI chr 1:142,948,942...142,992,410
Ensembl chr 1:142,950,540...142,992,615
|
|
G |
Slc28a2 |
solute carrier family 28 member 2 |
increases transport |
ISO |
SLC28A2 protein results in increased transport of Uridine |
CTD |
PMID:10087507 |
|
NCBI chr 3:114,355,003...114,647,382
Ensembl chr 3:114,355,798...114,647,382
|
|
G |
Slc29a1 |
solute carrier family 29 member 1 |
multiple interactions increases uptake |
ISO EXP |
4-nitrobenzylthioinosine inhibits the reaction [[SLC29A1 protein co-treated with SLC29A2 protein] results in increased uptake of Uridine]; 4-nitrobenzylthioinosine inhibits the reaction [SLC29A1 protein results in increased uptake of Uridine]; [SLC29A1 protein co-treated with SLC29A2 protein] results in increased uptake of Uridine; Dilazep inhibits the reaction [SLC29A1 protein results in increased uptake of Uridine]; Dipyridamole inhibits the reaction [SLC29A1 protein results in increased uptake of Uridine]; Dipyridamole promotes the reaction [4-nitrobenzylthioinosine inhibits the reaction [[SLC29A1 protein co-treated with SLC29A2 protein] results in increased uptake of Uridine]]; Lidoflazine inhibits the reaction [SLC29A1 protein results in increased uptake of Uridine] 4-nitrobenzylthioinosine inhibits the reaction [SLC29A1 protein results in increased uptake of Uridine]; Adenosine inhibits the reaction [SLC29A1 protein results in increased uptake of Uridine]; Cytidine inhibits the reaction [SLC29A1 protein results in increased uptake of Uridine]; Guanosine inhibits the reaction [SLC29A1 protein results in increased uptake of Uridine]; Inosine inhibits the reaction [SLC29A1 protein results in increased uptake of Uridine]; Thymidine inhibits the reaction [SLC29A1 protein results in increased uptake of Uridine]; Uridine inhibits the reaction [SLC29A1 protein results in increased uptake of Uridine] 2'-deoxyadenosine inhibits the reaction [SLC29A1 protein results in increased uptake of Uridine]; 4-nitrobenzylthioinosine inhibits the reaction [SLC29A1 protein results in increased uptake of Uridine]; Cytidine inhibits the reaction [SLC29A1 protein results in increased uptake of Uridine]; Dilazep inhibits the reaction [SLC29A1 protein results in increased uptake of Uridine]; Dipyridamole inhibits the reaction [SLC29A1 protein results in increased uptake of Uridine]; Guanosine inhibits the reaction [SLC29A1 protein results in increased uptake of Uridine]; Inosine inhibits the reaction [SLC29A1 protein results in increased uptake of Uridine]; Thymidine inhibits the reaction [SLC29A1 protein results in increased uptake of Uridine] |
CTD |
PMID:9353301 PMID:9396714 PMID:10366666 PMID:11085929 PMID:18381442 |
|
NCBI chr 9:17,784,468...17,799,008
Ensembl chr 9:17,784,468...17,799,005
|
|
G |
Slc29a2 |
solute carrier family 29 member 2 |
multiple interactions increases uptake |
ISO EXP |
4-nitrobenzylthioinosine inhibits the reaction [[SLC29A1 protein co-treated with SLC29A2 protein] results in increased uptake of Uridine]; [SLC29A1 protein co-treated with SLC29A2 protein] results in increased uptake of Uridine; Dipyridamole promotes the reaction [4-nitrobenzylthioinosine inhibits the reaction [[SLC29A1 protein co-treated with SLC29A2 protein] results in increased uptake of Uridine]] SLC29A2 protein results in increased uptake of Uridine 2'-deoxyadenosine inhibits the reaction [SLC29A2 protein results in increased uptake of Uridine]; Adenine inhibits the reaction [SLC29A2 protein results in increased uptake of Uridine]; Cytidine inhibits the reaction [SLC29A2 protein results in increased uptake of Uridine]; Dipyridamole inhibits the reaction [SLC29A2 protein results in increased uptake of Uridine]; Guanosine inhibits the reaction [SLC29A2 protein results in increased uptake of Uridine]; Inosine inhibits the reaction [SLC29A2 protein results in increased uptake of Uridine]; Thymidine inhibits the reaction [SLC29A2 protein results in increased uptake of Uridine] |
CTD |
PMID:9353301 PMID:9396714 PMID:10366666 PMID:11085929 |
|
NCBI chr 1:220,306,622...220,314,631
Ensembl chr 1:220,400,855...220,407,189 Ensembl chr 1:220,400,855...220,407,189
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO |
Uridine inhibits the reaction [tripterine results in increased expression of TP53 protein] |
CTD |
PMID:27374097 |
|
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
|
|
G |
Upp1 |
uridine phosphorylase 1 |
affects abundance multiple interactions increases metabolic processing |
ISO |
UPP1 protein affects the abundance of Uridine [UPP1 protein results in increased metabolism of Uridine] which affects the susceptibility to Fluorouracil; [UPP1 protein results in increased metabolism of Uridine] which affects the susceptibility to Pentobarbital |
CTD |
PMID:15772079 |
|
NCBI chr14:89,314,234...89,334,060
Ensembl chr14:89,314,176...89,334,276
|
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
EXP |
Uridine Triphosphate affects the folding of [Tetrachlorodibenzodioxin binds to AHR protein] |
CTD |
PMID:1848756 |
|
NCBI chr 6:54,963,990...55,001,806
Ensembl chr 6:54,963,990...55,001,464
|
|
G |
Calca |
calcitonin-related polypeptide alpha |
multiple interactions |
EXP |
Uridine Triphosphate promotes the reaction [Protons results in increased secretion of CALCA protein] |
CTD |
PMID:12044622 |
|
NCBI chr 1:184,184,018...184,188,922
Ensembl chr 1:184,184,020...184,188,911
|
|
G |
Egfr |
epidermal growth factor receptor |
increases phosphorylation |
EXP |
Uridine Triphosphate results in increased phosphorylation of EGFR protein |
CTD |
PMID:14676212 |
|
NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796
|
|
G |
Gnaq |
G protein subunit alpha q |
multiple interactions |
EXP |
Uridine Triphosphate inhibits the reaction [GNAQ protein promotes the reaction [Phenylephrine results in increased expression of NPPA protein]] |
CTD |
PMID:14676212 |
|
NCBI chr 1:233,382,778...233,622,584
Ensembl chr 1:233,382,708...233,622,786
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions |
ISO |
Uridine Triphosphate inhibits the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form] |
CTD |
PMID:32941855 |
|
NCBI chr 8:48,665,652...48,666,981
Ensembl chr 8:48,665,652...48,666,981
|
|
G |
Hcar2 |
hydroxycarboxylic acid receptor 2 |
multiple interactions |
ISO |
[Nicotinic Acids results in increased activity of HCAR2 protein] promotes the reaction [[Uridine Triphosphate results in increased phosphorylation of and results in increased activity of MAPK1 protein] which results in increased abundance of Arachidonic Acids]; [Nicotinic Acids results in increased activity of HCAR2 protein] promotes the reaction [[Uridine Triphosphate results in increased phosphorylation of and results in increased activity of MAPK3 protein] which results in increased abundance of Arachidonic Acids] |
CTD |
PMID:16674924 |
|
NCBI chr12:38,160,464...38,161,546
Ensembl chr12:38,160,464...38,161,546
|
|
G |
Il6 |
interleukin 6 |
multiple interactions increases expression |
ISO |
NF157 compound inhibits the reaction [Uridine Triphosphate results in increased expression of IL6 protein]; Suramin inhibits the reaction [Uridine Triphosphate results in increased expression of IL6 protein] MRS 2211 inhibits the reaction [Uridine Triphosphate results in increased expression of IL6 protein] |
CTD |
PMID:24793913 PMID:24849676 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
ISO EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Uridine Triphosphate results in increased phosphorylation of and results in increased activity of MAPK1 protein] which results in increased abundance of Arachidonic Acids]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Uridine Triphosphate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; [Nicotinic Acids results in increased activity of HCAR2 protein] promotes the reaction [[Uridine Triphosphate results in increased phosphorylation of and results in increased activity of MAPK1 protein] which results in increased abundance of Arachidonic Acids]; [Uridine Triphosphate results in increased phosphorylation of and results in increased activity of MAPK1 protein] which results in increased abundance of Arachidonic Acids; Uridine Triphosphate results in increased phosphorylation of and results in increased activity of MAPK1 protein RTKI cpd inhibits the reaction [Uridine Triphosphate results in increased phosphorylation of and results in increased activity of MAPK1 protein] Uridine Triphosphate results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:14676212 PMID:15034929 PMID:16674924 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Uridine Triphosphate results in increased phosphorylation of and results in increased activity of MAPK3 protein] which results in increased abundance of Arachidonic Acids]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Uridine Triphosphate results in increased phosphorylation of and results in increased activity of MAPK3 protein]; [Nicotinic Acids results in increased activity of HCAR2 protein] promotes the reaction [[Uridine Triphosphate results in increased phosphorylation of and results in increased activity of MAPK3 protein] which results in increased abundance of Arachidonic Acids]; [Uridine Triphosphate results in increased phosphorylation of and results in increased activity of MAPK3 protein] which results in increased abundance of Arachidonic Acids; Uridine Triphosphate results in increased phosphorylation of and results in increased activity of MAPK3 protein RTKI cpd inhibits the reaction [Uridine Triphosphate results in increased phosphorylation of and results in increased activity of MAPK3 protein] Uridine Triphosphate results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:14676212 PMID:15034929 PMID:16674924 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Myl2 |
myosin light chain 2 |
multiple interactions |
EXP |
Uridine Triphosphate inhibits the reaction [MYL2 protein promotes the reaction [Phenylephrine results in increased expression of NPPA protein]]; Uridine Triphosphate inhibits the reaction [MYOCD protein results in increased expression of MYL2 protein] |
CTD |
PMID:14676212 |
|
NCBI chr12:39,951,863...39,959,065
Ensembl chr12:39,951,987...39,958,239
|
|
G |
Myocd |
myocardin |
multiple interactions |
EXP |
Uridine Triphosphate inhibits the reaction [MYOCD protein results in increased expression of MYL2 protein]; Uridine Triphosphate inhibits the reaction [MYOCD protein results in increased expression of NPPA protein] |
CTD |
PMID:14676212 |
|
NCBI chr10:51,682,053...51,781,458
Ensembl chr10:51,683,540...51,778,986
|
|
G |
Nppa |
natriuretic peptide A |
multiple interactions increases expression |
EXP |
Uridine Triphosphate inhibits the reaction [GNAQ protein promotes the reaction [Phenylephrine results in increased expression of NPPA protein]]; Uridine Triphosphate inhibits the reaction [MYL2 protein promotes the reaction [Phenylephrine results in increased expression of NPPA protein]]; Uridine Triphosphate inhibits the reaction [MYOCD protein results in increased expression of NPPA protein]; Uridine Triphosphate inhibits the reaction [Phenylephrine results in increased expression of NPPA mRNA] Uridine Triphosphate results in increased expression of NPPA mRNA |
CTD |
PMID:14676212 |
|
NCBI chr 5:164,808,407...164,809,716
Ensembl chr 5:164,808,323...164,809,705
|
|
G |
P2ry2 |
purinergic receptor P2Y2 |
multiple interactions |
EXP ISO |
Uridine Triphosphate binds to and results in increased activity of P2RY2 protein Endocannabinoids inhibits the reaction [Uridine Triphosphate binds to and results in increased activity of P2RY2 protein]; Uridine Triphosphate binds to and results in increased activity of P2RY2 protein |
CTD |
PMID:15654852 PMID:30102254 |
|
NCBI chr 1:166,031,228...166,045,423
Ensembl chr 1:166,031,272...166,037,424
|
|
G |
P2ry4 |
pyrimidinergic receptor P2Y4 |
multiple interactions |
EXP |
Uridine Triphosphate binds to and results in increased activity of P2RY4 protein |
CTD |
PMID:15654852 |
|
NCBI chr X:70,421,599...70,447,109
Ensembl chr X:70,426,951...70,428,364
|
|
G |
Panx1 |
Pannexin 1 |
decreases activity |
ISO |
Uridine Triphosphate results in decreased activity of PANX1 protein |
CTD |
PMID:19023039 |
|
NCBI chr 8:13,567,185...13,606,040
Ensembl chr 8:13,566,739...13,606,040
|
|
G |
Sftpb |
surfactant protein B |
increases secretion |
ISO |
Uridine Triphosphate results in increased secretion of SFTPB protein |
CTD |
PMID:14565945 |
|
NCBI chr 4:100,166,855...100,175,941
Ensembl chr 4:100,166,863...100,175,938
|
|
G |
Sftpc |
surfactant protein C |
increases secretion |
ISO |
Uridine Triphosphate results in increased secretion of SFTPC protein |
CTD |
PMID:14565945 |
|
NCBI chr15:52,211,538...52,214,480
Ensembl chr15:52,211,544...52,214,616
|
|
G |
Tp53bp1 |
tumor protein p53 binding protein 1 |
multiple interactions |
ISO |
Uridine Triphosphate inhibits the reaction [Cesium-137 results in increased expression of and affects the localization of TP53BP1 protein] |
CTD |
PMID:32941855 |
|
NCBI chr 3:113,160,030...113,259,701
Ensembl chr 3:113,160,000...113,231,790
|
|
|
G |
Akt3 |
AKT serine/threonine kinase 3 |
multiple interactions |
EXP |
pyrimidin-2-one beta-ribofuranoside affects the reaction [Folic Acid affects the methylation of AKT3 gene] |
CTD |
PMID:24629913 |
|
NCBI chr13:95,076,308...95,348,913
Ensembl chr13:95,081,390...95,348,913
|
|
G |
Ankrd6 |
ankyrin repeat domain 6 |
decreases expression |
ISO |
pyrimidin-2-one beta-ribofuranoside results in decreased expression of ANKRD6 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 5:48,052,610...48,167,568
Ensembl chr 5:48,052,401...48,194,294
|
|
G |
Apaf1 |
apoptotic peptidase activating factor 1 |
affects expression |
ISO |
pyrimidin-2-one beta-ribofuranoside affects the expression of APAF1 mRNA |
CTD |
PMID:17133271 |
|
NCBI chr 7:31,699,309...31,784,192
Ensembl chr 7:31,699,885...31,784,192
|
|
G |
Apobec3 |
apolipoprotein B mRNA editing enzyme catalytic subunit 3 |
multiple interactions |
ISO |
[pyrimidin-2-one beta-ribofuranoside results in decreased activity of APOBEC3B protein] which results in increased susceptibility to Decitabine; pyrimidin-2-one beta-ribofuranoside inhibits the reaction [APOBEC3B protein results in decreased amination of Decitabine] |
CTD |
PMID:18398609 |
|
NCBI chr 7:121,108,108...121,128,346
Ensembl chr 7:121,109,241...121,128,542
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
ISO |
pyrimidin-2-one beta-ribofuranoside inhibits the reaction [Folic Acid results in decreased expression of APP protein] |
CTD |
PMID:26492244 |
|
NCBI chr11:24,425,013...24,641,872
Ensembl chr11:24,425,005...24,641,858
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
affects cleavage |
ISO |
pyrimidin-2-one beta-ribofuranoside affects the cleavage of BAX protein |
CTD |
PMID:19459041 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
affects cleavage decreases expression |
ISO |
pyrimidin-2-one beta-ribofuranoside affects the cleavage of BCL2 protein pyrimidin-2-one beta-ribofuranoside results in decreased expression of BCL2 protein |
CTD |
PMID:19459041 PMID:23320119 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Casp3 |
caspase 3 |
increases cleavage |
ISO |
pyrimidin-2-one beta-ribofuranoside results in increased cleavage of CASP3 protein |
CTD |
PMID:19459041 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp8 |
caspase 8 |
increases activity |
ISO |
pyrimidin-2-one beta-ribofuranoside results in increased activity of CASP8 protein |
CTD |
PMID:23320119 |
|
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
|
|
G |
Casp9 |
caspase 9 |
increases activity |
ISO |
pyrimidin-2-one beta-ribofuranoside results in increased activity of CASP9 protein |
CTD |
PMID:23320119 |
|
NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression |
ISO |
pyrimidin-2-one beta-ribofuranoside results in decreased expression of CCND1 protein |
CTD |
PMID:19459041 |
|
NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases expression |
ISO |
pyrimidin-2-one beta-ribofuranoside results in decreased expression of CDK2 protein |
CTD |
PMID:23320119 |
|
NCBI chr 7:3,124,953...3,132,533
Ensembl chr 7:3,124,954...3,132,457
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
decreases expression increases expression |
ISO |
pyrimidin-2-one beta-ribofuranoside results in decreased expression of CDKN1A protein pyrimidin-2-one beta-ribofuranoside results in increased expression of CDKN1A protein |
CTD |
PMID:19459041 PMID:23320119 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
increases phosphorylation |
ISO |
pyrimidin-2-one beta-ribofuranoside results in increased phosphorylation of CREB1 protein |
CTD |
PMID:18830594 |
|
NCBI chr 9:71,229,753...71,298,994
Ensembl chr 9:71,230,108...71,293,435
|
|
G |
Csgalnact2 |
chondroitin sulfate N-acetylgalactosaminyltransferase 2 |
increases expression |
ISO |
pyrimidin-2-one beta-ribofuranoside results in increased expression of CSGALNACT2 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 4:150,148,626...150,185,062
Ensembl chr 4:150,153,844...150,185,044
|
|
G |
Cux1 |
cut-like homeobox 1 |
decreases expression |
ISO |
pyrimidin-2-one beta-ribofuranoside results in decreased expression of CUX1 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr12:23,150,886...23,470,095
Ensembl chr12:23,151,180...23,445,074
|
|
G |
Derl1 |
derlin 1 |
increases expression |
ISO |
pyrimidin-2-one beta-ribofuranoside results in increased expression of DERL1 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 7:97,737,176...97,759,852
Ensembl chr 7:97,737,178...97,759,852
|
|
G |
Eif2ak2 |
eukaryotic translation initiation factor 2-alpha kinase 2 |
decreases response to substance decreases expression |
ISO |
EIF2AK2 protein results in decreased susceptibility to pyrimidin-2-one beta-ribofuranoside pyrimidin-2-one beta-ribofuranoside results in decreased expression of EIF2AK2 protein modified form |
CTD |
PMID:23320119 |
|
NCBI chr 6:1,428,845...1,466,193
Ensembl chr 6:1,428,834...1,466,201
|
|
G |
Esr1 |
estrogen receptor 1 |
increases expression |
ISO |
pyrimidin-2-one beta-ribofuranoside results in increased expression of ESR1 mRNA |
CTD |
PMID:19459041 |
|
NCBI chr 1:41,192,029...41,594,799
Ensembl chr 1:41,192,824...41,594,796
|
|
G |
H2ax |
H2A.X variant histone |
increases expression |
ISO |
pyrimidin-2-one beta-ribofuranoside results in increased expression of H2AX protein |
CTD |
PMID:17991895 |
|
NCBI chr 8:48,665,652...48,666,981
Ensembl chr 8:48,665,652...48,666,981
|
|
G |
Hsp90aa1 |
heat shock protein 90 alpha family class A member 1 |
decreases expression |
ISO |
pyrimidin-2-one beta-ribofuranoside results in decreased expression of HSP90AA1 protein |
CTD |
PMID:18830594 |
|
NCBI chr 6:135,107,262...135,112,793
Ensembl chr 6:135,107,271...135,112,775 Ensembl chr 6:135,107,271...135,112,775
|
|
G |
Igfbp3 |
insulin-like growth factor binding protein 3 |
affects expression |
ISO |
pyrimidin-2-one beta-ribofuranoside affects the expression of IGFBP3 mRNA |
CTD |
PMID:16505122 |
|
NCBI chr14:87,457,647...87,465,374
Ensembl chr14:87,457,647...87,465,374
|
|
G |
Junb |
JunB proto-oncogene, AP-1 transcription factor subunit |
affects expression |
ISO |
pyrimidin-2-one beta-ribofuranoside affects the expression of JUNB mRNA |
CTD |
PMID:16505122 |
|
NCBI chr19:26,092,972...26,094,756
Ensembl chr19:26,092,974...26,094,756
|
|
G |
Larp7 |
La ribonucleoprotein 7, transcriptional regulator |
increases expression |
ISO |
pyrimidin-2-one beta-ribofuranoside results in increased expression of LARP7 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 2:231,866,888...231,882,002
Ensembl chr 2:231,867,135...231,881,939
|
|
G |
Map1a |
microtubule-associated protein 1A |
increases expression |
ISO |
pyrimidin-2-one beta-ribofuranoside results in increased expression of MAP1A mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 3:113,251,918...113,272,193
Ensembl chr 3:113,251,778...113,272,186
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
decreases expression |
ISO |
pyrimidin-2-one beta-ribofuranoside results in decreased expression of MAPK1 protein modified form |
CTD |
PMID:23320119 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
decreases expression |
ISO |
pyrimidin-2-one beta-ribofuranoside results in decreased expression of MAPK3 protein modified form |
CTD |
PMID:23320119 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mapk8ip3 |
mitogen-activated protein kinase 8 interacting protein 3 |
increases expression |
ISO |
pyrimidin-2-one beta-ribofuranoside results in increased expression of MAPK8IP3 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr10:14,259,394...14,299,276
Ensembl chr10:14,260,787...14,299,167
|
|
G |
Mbd2 |
methyl-CpG binding domain protein 2 |
decreases expression |
ISO |
pyrimidin-2-one beta-ribofuranoside results in decreased expression of MBD2 protein |
CTD |
PMID:19459041 |
|
NCBI chr18:65,814,026...65,885,115
Ensembl chr18:65,814,026...65,885,114
|
|
G |
Mbd3 |
methyl-CpG binding domain protein 3 |
decreases expression |
ISO |
pyrimidin-2-one beta-ribofuranoside results in decreased expression of MBD3 protein |
CTD |
PMID:19459041 |
|
NCBI chr 7:12,179,046...12,186,251
Ensembl chr 7:12,179,203...12,186,656
|
|
G |
Mecp2 |
methyl CpG binding protein 2 |
decreases expression |
ISO |
pyrimidin-2-one beta-ribofuranoside results in decreased expression of MECP2 protein |
CTD |
PMID:19459041 |
|
NCBI chr X:156,650,389...156,713,813
Ensembl chr X:156,655,960...156,705,233
|
|
G |
Mtrf1l |
mitochondrial translation release factor 1 like |
increases expression |
ISO |
pyrimidin-2-one beta-ribofuranoside results in increased expression of MTRF1L mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 1:42,475,791...42,485,999
Ensembl chr 1:42,475,792...42,486,035
|
|
G |
Nfatc2ip |
nuclear factor of activated T-cells 2 interacting protein |
increases expression |
ISO |
pyrimidin-2-one beta-ribofuranoside results in increased expression of NFATC2IP mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 1:197,785,966...197,800,943
Ensembl chr 1:197,785,968...197,801,634
|
|
G |
Nfic |
nuclear factor I/C |
increases expression |
ISO |
pyrimidin-2-one beta-ribofuranoside results in increased expression of NFIC mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 7:11,151,941...11,179,544
Ensembl chr 7:11,152,038...11,177,664
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage |
ISO |
pyrimidin-2-one beta-ribofuranoside results in increased cleavage of PARP1 protein |
CTD |
PMID:19459041 |
|
NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
|
|
G |
Phldb1 |
pleckstrin homology-like domain, family B, member 1 |
decreases expression |
ISO |
pyrimidin-2-one beta-ribofuranoside results in decreased expression of PHLDB1 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 8:48,997,189...49,045,176
Ensembl chr 8:48,997,184...49,045,154
|
|
G |
Pml |
PML nuclear body scaffold |
decreases expression |
ISO |
pyrimidin-2-one beta-ribofuranoside results in decreased expression of PML mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 8:63,002,515...63,034,310
Ensembl chr 8:63,004,870...63,034,226
|
|
G |
Rabgap1l |
RAB GTPase activating protein 1-like |
decreases expression |
ISO |
pyrimidin-2-one beta-ribofuranoside results in decreased expression of RABGAP1L mRNA |
CTD |
PMID:19194470 |
|
NCBI chr13:77,975,392...78,609,009
Ensembl chr13:78,011,047...78,609,045
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
decreases expression |
ISO |
pyrimidin-2-one beta-ribofuranoside results in decreased expression of RB1 protein modified form |
CTD |
PMID:23320119 |
|
NCBI chr15:55,081,582...55,209,060
Ensembl chr15:55,083,140...55,209,342
|
|
G |
Rbm34 |
RNA binding motif protein 34 |
decreases expression |
ISO |
pyrimidin-2-one beta-ribofuranoside results in decreased expression of RBM34 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr19:59,874,745...59,894,981
Ensembl chr19:59,874,752...59,894,937
|
|
G |
Rrm2b |
ribonucleotide reductase regulatory TP53 inducible subunit M2B |
increases expression |
ISO |
pyrimidin-2-one beta-ribofuranoside results in increased expression of RRM2B mRNA |
CTD |
PMID:19010910 |
|
NCBI chr 7:76,750,045...76,780,817
Ensembl chr 7:76,750,050...76,780,817
|
|
G |
RT1-Bb |
RT1 class II, locus Bb |
increases expression |
ISO |
pyrimidin-2-one beta-ribofuranoside results in increased expression of HLA-DQB1 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr20:4,043,726...4,049,367
Ensembl chr20:4,039,413...4,049,711
|
|
G |
Sla |
src-like adaptor |
increases expression |
ISO |
pyrimidin-2-one beta-ribofuranoside results in increased expression of SLA mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 7:107,585,055...107,604,950
Ensembl chr 7:107,584,118...107,634,335
|
|
G |
Snip1 |
Smad nuclear interacting protein 1 |
decreases expression |
ISO |
pyrimidin-2-one beta-ribofuranoside results in decreased expression of SNIP1 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr15:19,275,273...19,282,753
Ensembl chr 5:143,063,099...143,070,884
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions decreases methylation |
ISO |
[pyrimidin-2-one beta-ribofuranoside results in decreased methylation of SOD2 gene] which results in increased expression of SOD2 protein; [pyrimidin-2-one beta-ribofuranoside results in decreased methylation of SOD2 promoter] which results in increased expression of SOD2 mRNA; [pyrimidin-2-one beta-ribofuranoside results in decreased methylation of SOD2 promoter] which results in increased expression of SOD2 protein |
CTD |
PMID:15908783 PMID:17895890 |
|
NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
|
|
G |
St3gal6 |
ST3 beta-galactoside alpha-2,3-sialyltransferase 6 |
increases expression |
ISO |
pyrimidin-2-one beta-ribofuranoside results in increased expression of ST3GAL6 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr11:44,176,518...44,237,119
Ensembl chr11:44,192,940...44,237,100
|
|
G |
Tfe3 |
transcription factor binding to IGHM enhancer 3 |
increases expression |
ISO |
pyrimidin-2-one beta-ribofuranoside results in increased expression of TFE3 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr X:15,574,579...15,587,826
Ensembl chr X:15,575,934...15,587,419
|
|
G |
Tp53 |
tumor protein p53 |
increases expression |
ISO |
pyrimidin-2-one beta-ribofuranoside results in increased expression of TP53 protein |
CTD |
PMID:23320119 |
|
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
|
|
G |
Wdr47 |
WD repeat domain 47 |
decreases expression |
ISO |
pyrimidin-2-one beta-ribofuranoside results in decreased expression of WDR47 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 2:211,380,894...211,441,817
Ensembl chr 2:211,381,036...211,441,815
|
|